Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Diabetes Reviews
  4. Volume 21, Issue 5
  5. Article
Volume 21, Issue 5
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417

Abstract

Background

DPP-4 inhibitors, or gliptins, are new oral antidiabetic drugs for type 2 diabetes. They help to regulate insulin and glucagon. These drugs have the advantage of a lower risk of hypoglycemia compared to some other diabetes medications and are typically prescribed when metformin and sulphonylureas have become less effective.

Objective

This review analyses a range of analytical and bioanalytical methods for DPP-4 inhibitors, that use spectroscopic techniques, chromatographic, and hyphenated techniques for analysis. So far, no review comprising all DPP-4 inhibitors has been presented. The primary objective of this review is to present the analysts with various analytical and bioanalytical methods for the quantification and estimation of DPP-4 inhibitors in different matrices.

Methods

To improve understanding, a review was carried out by creating a database of pre-existing research from digital sources such as ScienceDirect, and PubMed. The methodology is shown in the flowchart of the literature selection process.

Conclusion

The comprehensive assessment of methods for analysing DPP-4 inhibitors can be a valuable resource for researchers and healthcare practitioners. Hitherto, no review encompassing all DPP-4 inhibitors has been presented. Therefore, gaps in the data available on a particular subject, need to be required to collect data on a particular construct. The review suggests that chromatographic techniques were majorly used for analysis wherein solvents like acetonitrile, methanol, and buffer solutions were used as mobile phases that can deteriorate HPLC columns and equipment. So, scientists could investigate new methods for the assessment of DPP-4 inhibitors using more eco-friendly solvents.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdr/10.2174/0115733998288292240409060854
2024-05-03
2025-01-18

  • From This Site

    /content/journals/cdr/10.2174/0115733998288292240409060854
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SapraA. BhandariP. Diabetes (Nursing). In: StatPearls.Treasure Island, FLStatPearls Publishing2024
     [Google Scholar]
  2. SultanJ. AgarwalN. SharmaS. Characteristics and biological properties of imeglimin hydrochloride, a novel antidiabetic agent: A systematic review.Curr. Diabetes Rev.2024205e17102322228610.2174/011573399826033123100910403537855361
     [Google Scholar]
  3. SagandiraC.R. KhasipoA.Z. SagandiraM.B. WattsP. An overview of the synthetic routes to essential oral anti-diabetes drugs.Tetrahedron20219613237810.1016/j.tet.2021.132378
     [Google Scholar]
  4. DiabetesAvailable from: https://www.who.int/news-room/fact-sheets/detail/diabetes
  5. IDF diabetes atlas 2021.2021Available from: https://diabetesatlas.org/atlas/tenth-edition/
  6. DasH. GhoshS. GangulyD. MalakarS. BiswasP. GhoshD. Current scenario of diabetic mellitus with recent drug development approaches: A comprehensive review.Neuroquantology202321180182310.48047/nq.2023.21.01.NQ20062
     [Google Scholar]
  7. GanevaM. Safety profile of dipeptidyl peptidase-4 inhibitors.Trakia J. Sci.2023211546210.15547/tjs.2023.01.009
     [Google Scholar]
  8. ShaikhS. LeeE.J. AhmadK. AhmadS.S. LimJ.H. ChoiI. A comprehensive review and perspective on natural sources as dipeptidyl peptidase-4 inhibitors for management of diabetes.Pharmaceuticals202114659110.3390/ph1406059134203048
     [Google Scholar]
  9. MohdN.J. A review of dipeptidyl peptidase-4 (DPP-4) and its potential synthetic derivatives in the management of diabetes mellitus.Journal of Angiotherapy20248111210.25163/angiotherapy.819417
     [Google Scholar]
  10. SainiK. KhanY. SharmaS. How effective are gliflozins as DPP-4 inhibitors? a computational study.Theor. Found. Chem. Eng.202357340341010.1134/S0040579523030168
     [Google Scholar]
  11. ReghunathS.R. RashidM. ChandranV.P. ThungaG. ShivashankarK.N. AcharyaL.D. Factors contributing to the adverse drug reactions associated with the dipeptidyl peptidase-4 (DPP-4) inhibitors: A scoping review.Diabetes Metab. Syndr.202317710279010.1016/j.dsx.2023.10279037329838
     [Google Scholar]
  12. SainiK. SharmaS. KhanY. DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature.Front. Mol. Biosci.202310113062510.3389/fmolb.2023.113062537287751
     [Google Scholar]
  13. GallwitzB. Clinical use of DPP-4 inhibitors.Front. Endocrinol.20191038910.3389/fendo.2019.0038931275246
     [Google Scholar]
  14. Sitagliptin: Uses, interactions, mechanism of action.Available from: https://go.drugbank.com/drugs/DB01261
  15. Saxagliptin: Uses, interactions, mechanism of action.Available from: https://go.drugbank.com/drugs/DB06335
  16. Linagliptin: Uses, interactions, mechanism of action.Available from: https://go.drugbank.com/drugs/DB08882
  17. Vildagliptin: Uses, interactions, mechanism of action.Available from: https://go.drugbank.com/drugs/DB04876
  18. Alogliptin: Uses, interactions, mechanism of action.Available from: https://go.drugbank.com/drugs/DB06203
  19. Gemigliptin: Uses, interactions, mechanism of action.Available from: https://go.drugbank.com/drugs/DB12412
  20. Omarigliptin: Uses, interactions, mechanism of action.Available from: https://go.drugbank.com/drugs/DB11992
  21. Anagliptin: Uses, interactions, mechanism of action.Available from: https://go.drugbank.com/drugs/DB12417
  22. Teneligliptin: Uses, interactions, mechanism of action.Available from: https://go.drugbank.com/drugs/DB11950
  23. Trelagliptin: Uses, interactions, mechanism of action.Available from: https://go.drugbank.com/drugs/DB15323
  24. Evogliptin: Uses, interactions, mechanism of action.Available from: https://go.drugbank.com/drugs/DB12625
  25. XuS. TatosianD. McintoshI. Absorption, metabolism and excretion of [ 14 C]omarigliptin, a once-weekly DPP-4 inhibitor, in humans.Xenobiotica201848658459110.1080/00498254.2017.134633328665228
     [Google Scholar]
  26. FurutaS. SmartC. HackettA. BenningR. WarringtonS. Pharmacokinetics and metabolism of [ 14 C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans.Xenobiotica201343543244210.3109/00498254.2012.73161823075005
     [Google Scholar]
  27. ParkJ.W. KimK.A. ParkJ.Y. Development of a liquid chromatography/tandem‐mass spectrometry assay for the simultaneous determination of teneligliptin and its active metabolite teneligliptin sulfoxide in human plasma.Biomed. Chromatogr.2020342e472110.1002/bmc.472131656058
     [Google Scholar]
  28. MowakaS. AshoushN. TadrosM.M. AyoubB.M. Investigation of pharmacokinetic parameters of trelagliptin in Egyptian volunteers using sensitive LC-MS/MS: A comparative study with a Japanese population.J. Anal. Methods Chem.202120211910.1155/2021/966409934925935
     [Google Scholar]
  29. GuN. ParkM.K. KimT.E. Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.Drug Des. Devel. Ther.201481709172110.2147/DDDT.S6567825336915
     [Google Scholar]
  30. RavisankarP. MounikaG. DevadasuC. DevalaraoG. A simple validated UV Spectrophotometric method for quantitative analysis of Sitagliptin phosphate in pharmaceutical dosage form.J. Chem. Pharm. Res.202073254258
     [Google Scholar]
  31. AnudeepaJ. ManavalanR. VenkatanarayananR. Development of UV-spectrophotometric method for sitagliptin in bulk and pharmaceutical formulation.IJSTE2015351352135410.2348/ijset09151352
     [Google Scholar]
  32. SunkaraN. Neela ManeeshaK. LavanyaB. ArunkumarS. UV spectrophotometric method development and validation of sitagliptin in bulk and pharmaceutical dosage form.IJAPCR201733577580
     [Google Scholar]
  33. SushmaG HarshSD AnnapurnaMM Development and validation of new spectrophototmetric methods for the determination of sitagliptin.Acta Sci Pharm Sci20204301510.31080/ASPS.2020.04.0507
     [Google Scholar]
  34. PathadeP. Development and validation of stability indicating UV spectrophotometric method for the estimation of sitagliptin phosphate in bulk and tablet dosage form.J. Pharm. Res.201143
     [Google Scholar]
  35. TarkaseK.N. SarodeM.B. GulveS.A. GawadeA. Development and validation of UV spectrophotometric method for estimation of sitagliptin phosphate.Pharm. Lett.201353315318
     [Google Scholar]
  36. JalkoteR.N. KalshettiM.S. UV spectrophotometric method development and validation for determination of sitagliptin in API and in pharmaceutical dosage form.World J. Pharm. Pharm. Sci.20198591692510.20959/wjpps20195‑13681
     [Google Scholar]
  37. ChavhanV. KadamA. UV spectrophotometric method development and validation for estimation of sitagliptin phosphate in bulk and tablet dosage form by absorption ratio and area under the curve method.J Biolog Scient Opin20131431732210.7897/2321‑6328.01407
     [Google Scholar]
  38. JeyabalanG. NyolaN. Analytical method development and validation of sitagliptin phosphate monohydrate in pure and tablet dosage form by derivative spectroscopy.J. Appl. Pharm. Sci.201331959810.7324/JAPS.2013.30118
     [Google Scholar]
  39. MonilaN. Pratap PullaR. ShabadH. SwathiV. RajasekharJ. RameshA. New extractive method development of sitagliptin phosphate in API and its unit dosage forms by spectrophotometry.IOSR J. Pharm. Biol. Sci.201216374010.9790/3008‑0163740
     [Google Scholar]
  40. GhodeswarP. JainA. JainS. Development of First Order Derivative UV-Spectrophotometric Method for the Estimation of Sitagliptin Phosphate.Res J Pharm Technol201144631633
     [Google Scholar]
  41. PatilS. RameshB. HareeshA.R. PatilK. ValidatedU.V. Spectrophotometric method for estimation of sitagliptin phosphate in tablet dosage form.Res J Pharm Technol201033798800
     [Google Scholar]
  42. JainP. ChaudhariA. DesaiB. PatelS. PatelS. ShimpiH. Development and validation of first order derivative UV-spectrophotometric method for determination of sitagliptin in bulk and in formulation.IJDDR201134194199
     [Google Scholar]
  43. MasteM.M. BhatA.R. MohiteM. PatilD. Spectrophotometric method for estimation of sitagliptin phosphate in bulk and tablet dosage form.IJPFA2011224750
     [Google Scholar]
  44. SekaranB.C. RaniP.A. Development and validation of spectrophotometric method for the determination of DPP-4 inhibitor, sitagliptin, in its pharmaceutical preparations.Eclét. Quím.20103534553
     [Google Scholar]
  45. TapkirA.S. BiradarS.M. ChaudhariP.D. Development and validation of stability indicating HPTLC assay method for estimation of sitagliptin phosphate.Int. J. Pharm. Sci. Res.2017810445410.13040/IJPSR.0975‑8232.8(10).4454‑60
     [Google Scholar]
  46. AhmedR.M. HadadG.M. El-GendyA.E. IbrahimA. Development of HPLC method for determination of sitagliptin in human plasma using fluorescence detector by experimental design approach.Anal. Chem. Lett.20188681382810.1080/22297928.2018.1545603
     [Google Scholar]
  47. DayyihW.A. HamadM. Determination of sitagliptin levels in rats serum by HPLC and its pharmacokinetic investigation in existence of sucralose.Indones. J. Pharm.201829311712610.14499/indonesianjpharm29iss3pp117
     [Google Scholar]
  48. ZaidA.N. ZaarorA.Y. KaddumiA. Stability of extemporaneously prepared sitagliptin phosphate solution.PLoS One2022173e026206810.1371/journal.pone.026206835294449
     [Google Scholar]
  49. IqbalQ. BashirS. JanS.U. MalikM.Z. AfzalI. KhalidA. Development of a rapid resolution HPLC method for the quantitative determination of sitagliptin in Human plasma.Pak. J. Pharm. Sci.201831379579929716857
     [Google Scholar]
  50. FaresM. Al-AniI. HailatM. KhaleelA. CollierP. Al-AniA. Evaluation the impact of grapefruit juice on sitagliptin pharmacokinetics in healthy rats.Int J Pharm Res20211322145215310.31838/ijpr/2021.13.02.271
     [Google Scholar]
  51. GiordaniA.C.F. CampanharoS. WingertR.N. BuenoM.L. ManoelW.J. GarciaV.C. Determination of sitagliptin in the presence of its organic impurities using Box-Behnken experimental design for robustness assessment.Pharmazie201873844244610.1691/ph.2018.7201
     [Google Scholar]
  52. ReddyV.R.B. RamanN. KumarS.B. RambabuC. Chiral separation of sitagliptin phosphate enantiomer by HPLC using amylose based chiral stationary phase.J. Pharm. Res.20137654655010.1016/j.jopr.2013.06.014
     [Google Scholar]
  53. MoneM.K. JainP. KurhadeS. SonuneD.P. KaduskarR.D. Development and validation of a liquid chromatographic enantiomer separation method for the estimation of (S)-enantiomer in sitagliptin.Int. J. Pharm. Sci. Res.2014562382238610.13040/IJPSR.0975‑8232.5(6).2382‑86
     [Google Scholar]
  54. SpandanaT. GoliV.V.N. GurupadayyaB. In vitro study and pharmacokinetic evaluation of sitagliptin phosphate enantiomers in rat plasma.Bioanalysis202315161033104710.4155/bio‑2023‑008437431826
     [Google Scholar]
  55. RavanelloA. DelgadoS.L. MarcolinoI.P.A. CodevillaF.C. AdamsI.H.A. RolimM.R.C. A simple stability-indicating LC-UV method to assay sitagliptin phosphate in tablets.Curr. Anal. Chem.20128456957310.2174/157341112803216771
     [Google Scholar]
  56. GumieniczekA. BereckaA. MroczekT. WojtanowskiK. DąbrowskaK. StępieńK. Determination of chemical stability of sitagliptin by LC-UV, LC-MS and FT-IR methods.J. Pharm. Biomed. Anal.201916478980710.1016/j.jpba.2018.11.02330503802
     [Google Scholar]
  57. D S, E S, E S, Bakshi VDevelopment and Validation of RP-HPLC Method for the Estimation of Sitagliptin Phosphate in Tablet Dosage Form.Int. J. Pharm. Sci. Res.201723414510.21477/ijapsr.v2i3.8099
     [Google Scholar]
  58. SultanaS. HossainM.S. IslamM.S. RoufA.S.S. Quantitation of sitagliptin in drug product by validated reversed phase liquid chromatographic technique.Dhaka Univ J Pharm Sci201817112312910.3329/dujps.v17i1.37128
     [Google Scholar]
  59. MasteM.M. ParateA.N. BhatA.R. Validation and application of a high-performance liquid chromatography method for estimation of sitagliptin phosphate from bulk drug and pharmaceutical formulation.Asian J. Res. Chem20114914661468
     [Google Scholar]
  60. QassasK.M. MardinA.M. GhazaH. A validated HPLC stability indicating method for the determination of sitagliptin in bulk drug substance and tablets.Int. J. Pharm. Sci. Rev. Res.2015321194198
     [Google Scholar]
  61. DangiN.S. BavaskarS.R. BarhateS.D. Development and validation of RP-HPLC method for the estimation of sitagliptin phosphate in bulk and tablet dosage form.World J. Pharm. Res.20165977378110.20959/wjpr20169‑6878
     [Google Scholar]
  62. PhanisriM. LakshmiM.J. RamaD. ReddyB. PadmalathaH. Development and validation of RP-HPLC method for quantitative estimation of sitagliptin phosphate in bulk and pharmaceutical dosage forms.World J. Pharm. Res.20176161093111010.20959/wjpr201716‑10282
     [Google Scholar]
  63. DalawaiV.M. SanasiD.P. SharmaK.H. Development and validation of simple effective HPLC method for the quantitative determination of related substance present in sitagliptin phosphate drug substance.Int. J. Pharm. Sci. Res.2016741210.13040/IJPSR.0975‑8232.7(4).1493‑02
     [Google Scholar]
  64. PunagotiR.A. MouryaR. Development and validation of new RP-HPLC method for the quantitative estimation of sitagliptin phosphate in bulk and tablet dosage form.Int. J. Adv. Sci. Res.2021123301305
     [Google Scholar]
  65. SalehO.A. AzzounyE.A.A.E.S. EneinA.H.Y. BadaweyA.M. A validated stability indicating HPLC method for determination of sitagliptin.Eur. J. Chem.20145349750210.5155/eurjchem.5.3.497‑502.1080
     [Google Scholar]
  66. PamuS. PatyarS. ThakkalapallyL. Development and validation of a novel RP-HPLC analytical method for sitagliptin determination in human plasma.J. Pharm. Res. Int.20213342B9210110.9734/jpri/2021/v33i42B32430
     [Google Scholar]
  67. RayidiL. YunoosMd. Development and validation of RP-HPLC method for the estimation of sitagliptin phosphate in bulk and its tablet dosage form.J. Adv. Pharm. Educ. Res.201334475479
     [Google Scholar]
  68. El-BagaryR.I. ElkadyE.F. AyoubB.M. Simultaneous determination of sitagliptin and metformin in ternary mixture with sitagliptin acid degradation product.Eur. J. Chem.20134436036510.5155/eurjchem.4.4.360‑365.843
     [Google Scholar]
  69. MuhammadA. MuhammadN.S. MuhammadM.H. RahmanJ. EjazS. AltafH. Development and validation of an HPLC method for the quantification of sitagliptin in plasma and tablet dosage form.Lat. Am. J. Pharm.2015343456461
     [Google Scholar]
  70. SonuneD.P. MoneM.K. Isolation, characterization of degradation products of sitagliptin and development of validated stability-indicating HPLC assay method for sitagliptin API and tablets.Int. J. Pharm. Sci. Res.2013493494350310.13040/IJPSR.0975‑8232.4(9).3494‑03
     [Google Scholar]
  71. KumarD.P. JhansiT.N. RaoG.S. JainK.K. Method development and validation for enantiomer in sitagliptin hydrochloride by RPHPLC.J. Chem. Pharm. Res.20179121317
     [Google Scholar]
  72. RameshT. RaoN.P. SureshK. Enantiomeric separation of sitagliptin by a validated chiral liquid chromatographic method.Anal. Methods20146122322810.1039/C3AY41626G
     [Google Scholar]
  73. GawandeV. NarvekarS. RathorP. SinghA.K. AjgaonkarA. BamburdekarS. Simple, rapid RP-HPLC method for estimation of sitagliptin from urine and its application in pharmacokinetics.Int. J. Bioassays201321013221326
     [Google Scholar]
  74. GaddalaD. SubudhiS.K. SnigdhaD. RP-HPLC method development and validation for the determination of sitagliptin in bulk and pharmaceutical dosage form.IJARMPS20194101927
     [Google Scholar]
  75. VuyyuruN.R. KrishnaG.V. RamadeviB. KumarY.R. Evaluation of process impurities and degradants of sitagliptin phosphate by validated stability indicating RP-LC method.Asian J. Chem.20172991941194710.14233/ajchem.2017.20632
     [Google Scholar]
  76. TangY. LiX. WenN. SunX. YuM. LiZ.G. RP-HPLC determination of the content and the related substances of sitagliptin phosphate.Yaowu Fenxi Zazhi200929813701372
     [Google Scholar]
  77. PatilS. RameshB. HareeshA. PatilK. DhokaneA. Development and validation of RP-HPLC method for the estimation of sitagliptin phosphate in tablet dosage form.Asian J. Res. Chem201033653655
     [Google Scholar]
  78. LohG.O.K. WongE.Y.L. TanY.T.F. Simple and rapid LC-MS/MS method for determination of sitagliptin in human plasma and application to bioequivalence study.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.2020115912233710.1016/j.jchromb.2020.12233732905988
     [Google Scholar]
  79. RochaenyH. IrawanC. SaputroI.D. RahmatiaL. MawaddahN.I. Development and validation of an Ultra performance liquid chromatography-tandem mass spectrometry method with liquid-liquid extraction for the quantification of sitagliptin in human plasma using nebivolol as internal standard.Res J Pharm Tech2022151899610.52711/0974‑360X.2022.00016
     [Google Scholar]
  80. MoonS.J. YuK.S. KimM.G. An assessment of pharmacokinetic interaction between lobeglitazone and sitagliptin after multiple oral administrations in healthy men.Clin. Ther.20204261047105710.1016/j.clinthera.2020.04.00532362346
     [Google Scholar]
  81. IsmailK.M. RaoA.L. RaoM.B. Estimation of sitagliptin in K2EDTA human plasma using UHPLC-MS/MS method.Int. J. Pharm. Chem. Biol. Sci.201774459467
     [Google Scholar]
  82. JoshiD. SinghB. RautelaA. SemwalN. Analytical method development and validation of UV-visible spectrophotometric method for the estimation of saxagliptin in gastric medium.Glob J Pharm Pharmaceut Sci202182596510.19080/GJPPS.2021.08.555735
     [Google Scholar]
  83. KoliS.N. BelvotagiA.V. MudkeR.P. PatilS.A. UV spectrophotometric method development and validation for estimation of saxagliptin in API and in pharmaceutical dosage form.Int. J. Pharm. Pharm. Res.2019144166179
     [Google Scholar]
  84. PrasadV. GoudaN. Determination of saxagliptin monohydrate by derivatization UV-vis spectroscopy.Int. J. Sci. Res.2021101135335510.21275/SR20610163533
     [Google Scholar]
  85. DeshpandeS.V. RoyM.A. DaswadkarS.C. Development and validation of UV spectrophotometric method for estimation of saxagliptin in bulk and pharmaceutical dosage form.Int J Pharm Drug Anal2016413034
     [Google Scholar]
  86. MadhukarA. MahajanS.R. SiralV.R. RathodR.B. IngoleB.S. Method development and validation of saxagliptin by using UV spectrophotometric and RP-HPLC techniques in bulk and tablet dosage form.J. Pharma Res.20231221524
     [Google Scholar]
  87. ShindeB.S. KalshettiM.S. KokaneA.P. UV-spectrophotometric method development and validation for estimation of saxagliptin in API and pharmaceutical dosage form.Int. J. Curr. Pharm. Res.2020125636610.22159/ijcpr.2020v12i5.39768
     [Google Scholar]
  88. BhavyaE. DhereM.D. Development of UV spectrophotometric method for estimation of saxagliptin pharmaceutical dosage forms.J. Pharm. Negat. Results20221399362937110.47750/pnr.2022.13.S09.1094
     [Google Scholar]
  89. MoneebM.S. Spectrophotometric and spectrofluorimetric methods for the determination of saxagliptin and vildagliptin in bulk and pharmaceutical preparations.Bull. Fac. Pharm. Cairo Univ.201351213915010.1016/j.bfopcu.2013.03.003
     [Google Scholar]
  90. GurralaS. RajS. CvsS. AnumoluD.P. NaraparajuS. NizampetH. Response surface methodology in spectrophotometric estimation of saxagliptin, derivatization with MBTH and ninhydrin.Turk J Pharm Sci202219191810.4274/tjps.galenos.2021.9319535227036
     [Google Scholar]
  91. SrividyaS. SwethaE. VeereshamC. Development and validation of a High Performance Thin Layer Chromatographic method for quantitative analysis of saxagliptin.Am. J. Anal. Chem.201561079780610.4236/ajac.2015.610076
     [Google Scholar]
  92. ZinjadS.S. GaikwadD.D. Analytical method development of saxagliptin HCl by RP-HPLC.J. Drug Deliv. Ther.20199427427810.22270/jddt.v9i4.3040
     [Google Scholar]
  93. Chhabda PawanjeetJ. BalajiM. SrinivasaraoV. ApparaoK.M.C. Development and validation of simple stability indicating RP-HPLC method for analysis of saxagliptin and its forced degradation impurities in bulk drug and pharmaceutical dosage form.IJRDPL2014339931003
     [Google Scholar]
  94. KarkhanisV.V. CaptainA.D. Development and validation of a liquid chromatographic method for estimation of saxagliptin in tablet dosage form.Asian J. Res. Chem201366552554
     [Google Scholar]
  95. ScheerenL.E. MarcolinoA.I.P. AdamsA.I.H. RolimC.M.B. Stability indicating RP-LC-PDA method for the quantitative analysis of saxagliptin in pharmaceutical dosage form.Braz. J. Pharm. Sci.201551246146610.1590/S1984‑82502015000200023
     [Google Scholar]
  96. Abdel-GhanyM.F. Abdel-AzizO. AyadM.F. TadrosM.M. Stability-indicating liquid chromatographic method for determination of saxagliptin and structure elucidation of the major degradation products using LC-MS.J. Chromatogr. Sci.201553455456410.1093/chromsci/bmu08425060753
     [Google Scholar]
  97. GaoJ. YuanY. LuY. YaoM. Development of a rapid UPLC‐MS/MS method for quantification of saxagliptin in rat plasma and application to pharmacokinetic study.Biomed. Chromatogr.201226121482148710.1002/bmc.272022334441
     [Google Scholar]
  98. SahloulL. SalamiM. Development and validation of a new analytical method for determination of linagliptin in bulk by visible spectrophotometer.Sci. Rep.2023131408310.1038/s41598‑023‑31202‑w36906687
     [Google Scholar]
  99. MishraM. VermaG. Analytical method development and validation for determination of linagliptin in bulk and dosage form by UV spectroscopy.J. Emerg. Technol. Innov. Res.201857908912
     [Google Scholar]
  100. GurralaS. AnumoluP.D. MenkanaS. GandlaN. ToddiK. Spectrophotometric estimation of linagliptin using ion-pair complexation and oxidative coupling reactions – A green approach.Thaiphesatchasan2020444245250
     [Google Scholar]
  101. JoshiD. SinghB. RautelaA. SemwalN. Analytical method development and validation of UV-visible spectrophotometric method for the estimation of linagliptin.Glob J Nanomed20215555567110.19080/GJN.2021.05.555671
     [Google Scholar]
  102. DalalA. TegeliV. WaghmodeR. Development and validation of a simple and rapid UV spectrophotometric method for linagliptin in bulk and marketed dosage form.Der Pharma Chemica20221422326
     [Google Scholar]
  103. BholeR.P. WankhedeS.B. ZambareY.B. WankhedeT.S. High performance thin layer chromatographic determination of linagliptin in pharmaceutical formulations and in biological samples.Int J Pharmaceut Chem Analy201741131910.18231/2394‑2797.2017.0004
     [Google Scholar]
  104. HanafyA. MahgoubH. A validated HPLC method for the determination of linagliptin in rat plasma. Application to a pharmacokinetic study.J. Chromatogr. Sci.20165491573157710.1093/chromsci/bmw10627353348
     [Google Scholar]
  105. MouradS.S. El-KimaryE.I. HamdyD.A. BararyM.A. Stability-indicating HPLC-DAD method for the determination of linagliptin in tablet dosage form: Application to degradation kinetics.J. Chromatogr. Sci.20165491560156610.1093/chromsci/bmw10327334290
     [Google Scholar]
  106. RajbangshiJ.C. AlamM.M. HossainM.S. IslamM.S. RoufA.S.S. Development and validation of a RP-HPLC method for quantitative analysis of linagliptin in bulk and dosage forms.Dhaka Univ J Pharm Sci201817217518210.3329/dujps.v17i2.39173
     [Google Scholar]
  107. AyoubB.M. El-BagaryR.I. ElkadyE.F. Liquid chromatographic determination of linagliptin in bulk, in plasma and in its pharmaceutical preparation.Int. J. Biomed. Sci.20128320921410.59566/IJBS.2012.820923675275
     [Google Scholar]
  108. Al-SabtiB. HarbaliJ. Trace analysis of potential genotoxic impurity N, N ‐dimethylaniline in linagliptin active pharmaceutical ingredient using HPLC.Separ. Sci. Plus20203730631210.1002/sscp.202000026
     [Google Scholar]
  109. Al-SabtiB. HarbaliJ. Quantitative determination of potential genotoxic impurity 3‐aminopyridine in linagliptin active pharmaceutical ingredient using HILIC–UV.Biomed. Chromatogr.20203411e493010.1002/bmc.493032579716
     [Google Scholar]
  110. Nagabhusana RaoT. SankarG.G. RaniJ.L. High throughput LC-MS/MS method for the quantitation of linagliptin in human plasma by solid phase extraction using 96 well plate format.Int. J. Pharm. Sci. Res.2016731321133010.13040/IJPSR.0975‑8232.7
     [Google Scholar]
  111. KumariB. KhansiliA. Analytical method development and validation of UV-visible spectrophotometric method for the estimation of vildagliptin in gastric medium.Drug Res.202070941742310.1055/a‑1217‑029632746479
     [Google Scholar]
  112. PrasadP.V. DivyaK. RamanaM.V. KrishnaveniA. VinayJ. MahadeswarM. Analytical method development and validation for the estimation of vildagliptin in bulk and its dosage form using UV spectrophotometer.Indo Am J Pharm Res201771210691076
     [Google Scholar]
  113. NaveedS. RehmanH. QamarF. ZainabS. Method development and validation of Vildagliptin using UV spectrophotometer.Int. J. Pharm. Sci. Res.2014510714717
     [Google Scholar]
  114. SwathiC.A. SanthiO.K. SupriyaV. ShakirunnisaS.K. SandhyaT. PadmalathaR.K. Method development and validation of vildagliptin in tablets and dosage form by UV spectrophotometer.World J. Pharm. Pharm. Sci.20211081830184210.20959/wjpps20218‑19577
     [Google Scholar]
  115. AnsariA. ChadchankarR. JadhavV. PatilS. UV spectroscopy method development and validation for determination of vildagliptin in bulk and formulation.World J. Pharm. Pharm. Sci.20221152154216110.20959/wjpps20225‑22104
     [Google Scholar]
  116. GaikwadG.A. TambeP.P. Development and validation of UV spectroscopic method for estimation of vildagliptin in tablet dosage form.EJBPS202298427432
     [Google Scholar]
  117. ManeS.S. KhanM.A. Development of UV-Visible spectrophotometric method for the estimation of vildagliptin in different medium.JPharm Biol Sci2023102838710.18231/j.jpbs.2022.016
     [Google Scholar]
  118. SafilaN. ZehraA. MuhammadT.A. Using UV spectrophotometric method to determine the linearity of vildagliptin brands.Am J Innov Res Appl Sci20151169
     [Google Scholar]
  119. Thomas BardenA. PiccoliB.L. VolpatoN.M. SteppeM. Second-order derivative UV spectrophotometric and RP-HPLC methods for the analysis of vildagliptin and application for dissolution study.Drug Analyt Res201821465310.22456/2527‑2616.86511
     [Google Scholar]
  120. HoushehS. MohammadH. AlahmadY. Spectrophotometric method for the determination of vildagliptin in bulk and pharmaceutical dosage forms.Int. J. Pharm. Sci. Rev. Res.2019582117120
     [Google Scholar]
  121. DayoubL.A. AmaliF. Development of a new visible spectrophotometric analytical method for determination of vildagliptin in bulk and pharmaceutical dosage forms.Res J Pharm Technol20201362807281010.5958/0974‑360X.2020.00499.0
     [Google Scholar]
  122. PatilK.R. DeshmukhT.A. PatilV.R. A stability indicating HPTLC method development and validation for analysis of vildagliptin as bulk drug and from its pharmaceutical dosage form.Int. J. Pharm. Sci. Res.20201152310231610.13040/IJPSR.0975‑8232.11
     [Google Scholar]
  123. BoovizhikannanT. PalanirajanV.K. RP-HPLC determination of vildagliptin in pure and in tablet formulation.J. Pharm. Res.20137111311610.1016/j.jopr.2013.01.001
     [Google Scholar]
  124. kumar AS, Sandhya A, Vaibhav J, Jain A, Chavhan A. Development of RP-HPLC method for vildagliptin in pharmaceutical dosage form.Int. J. Pharm. Sci. Rev. Res.2023781364010.47583/ijpsrr.2023.v78i01.006
     [Google Scholar]
  125. KashidA.M. GhorpadeD.A. ToranmalP.P. DhawaleS.C. Development and validation of reversed phase HPLC method for the determination of vildagliptin using an experimental design.J. Anal. Chem.201570451051510.1134/S1061934815040061
     [Google Scholar]
  126. RaoK.H. RaoA.L. SekharK.B.C. Development and validation of HPLC method for the estimation of vildagliptin in pharmaceutical dosage form.Int. J. Pharm. Chem. Biol. Sci.201420142361366
     [Google Scholar]
  127. RaosahebJ.R. DabhadeM.P. KokateS.V. ShindeV.S. ShaikhW.C. RP-HPLC method development and validation of vildagliptin in bulk and dosage form.World J. Pharm. Pharm. Sci.2017691161117610.20959/wjpps20179‑9980
     [Google Scholar]
  128. SatpathyP.R. GoudV.M. BhagyaB. SharmaJ.V.C. ShyamalaN. Development and validation of RP-HPLC method for the assay of vildagliptin.World J. Pharm. Pharm. Sci.20143223032310
     [Google Scholar]
  129. MalakarA. BokshiB. NasrinD. Development and validation of RP-HPLC method for estimation of Vildagliptin from table dosage form.Int. J. Pharma Sci.201211909810.3329/ijpls.v1i1.12947
     [Google Scholar]
  130. SultanaR. BacharS.C. RahmanF. Development and validation of stability indicating assay method of vildagliptin in bulk and tablet dosage form by RP-HPLC.Int J Pharm Sci Life Sci20134425302534
     [Google Scholar]
  131. ChaphekarM.M. HamrapurkarP. Development and validation of RP-HPLC assay method for vildagliptin using Qbd approach and its application to forced degradation studies.Int. J. Pharm. Sci. Drug Res.20168315716510.25004/IJPSDR.2016.080306
     [Google Scholar]
  132. SavaleS.K. Development and validation of RP-HPLC method for estimation of vildagliptin.Asian J Biomater Res201735611
     [Google Scholar]
  133. KhatunR. MirazzunnabiM. A validated reversed-phase hplc method for the determination of vildagliptin from tablet dosage form.Int J Pharm Sci Life Sci201323909810.3329/ijpls.v2i3.15455
     [Google Scholar]
  134. BagaryE.R.I. ElkadyE.F. AyoubB.M. Liquid chromatographic methods for the determination of vildagliptin in the presence of its synthetic intermediate and the simultaneous determination of pioglitazone hydrochloride and metformin hydrochloride.Int. J. Biomed. Sci.201173201208
     [Google Scholar]
  135. Al-QudahE. ArarS. SweidanK. Forced degradation studies of vildagliptin raw material alone and in the presence of excipients using HPLC-UV analysis.J. Excip. Food Chem.20201122941
     [Google Scholar]
  136. BardenA.T. SalamonB. SchapovalE.E.S. SteppeM. Stability-indicating RP-LC method for the determination of vildagliptin and mass spectrometry detection for a main degradation product.J. Chromatogr. Sci.201250542643210.1093/chromsci/bms02422511486
     [Google Scholar]
  137. WaghuldeM. NaikJ. Development and validation of analytical method for vildagliptinencapsulated poly-ε-caprolactone microparticles.Mater. Today Proc.20185195896410.1016/j.matpr.2017.11.171
     [Google Scholar]
  138. PharneA.B. SanthakumariB. GhemudA.S. JainH.K. KulkarniM.J. Bioanalytical method development and validation of vildagliptin a novel dipeptidyl peptidase IV inhibitor by RP-HPLC method.Int. J. Pharm. Pharm. Sci.201243119123
     [Google Scholar]
  139. PeluriK. RajasekaranS. Stability-indicating RP-UPLC method for determination of vildagliptin in drug substance and its tablet dosage form.J. Pharm. Res. Int.20213345A13914610.9734/jpri/2021/v33i45A32726
     [Google Scholar]
  140. KumarN. DevineniS.R. SinghG. KadirappaA. DubeyS.K. KumarP. Identification, isolation and characterization of potential process-related impurity and its degradation product in vildagliptin.J. Pharm. Biomed. Anal.201611911412110.1016/j.jpba.2015.11.04426678178
     [Google Scholar]
  141. GiordaniF.A.C. CampanharoS. WingertR.N. UPLC-ESI/Q-TOF MS/MS method for determination of vildagliptin and its organic impurities.J. Chromatogr. Sci.202058871872510.1093/chromsci/bmaa04032705127
     [Google Scholar]
  142. de AndradeC. de LockA.A.G. PigattoM.C. HaasS.E. CostaT.D. de AraújoB.V. Validation of LC‐MS/MS method applied to evaluation of free tissue concentrations of vildagliptin in diabetic rats by microdialysis.Biomed. Chromatogr.201428121722172710.1002/bmc.321224771661
     [Google Scholar]
  143. TiwariA. SethiV.A. SiddiquiA.W. PanigrahyB.K. KhurooA.H. TyagiL.K. Bioanalytical method development and validation of vildagliptin in rat plasma using LCMS/MS method.Int. J. Adv. Sci. Res.20191032229
     [Google Scholar]
  144. SakthimanigandanK. GaneshM. KanthikiranV. SivakumarT. JangH. Liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the determination of Vildagliptin in rat plasma.Acta Chromatogr.201527229530710.1556/AChrom.27.2015.2.7
     [Google Scholar]
  145. UçaktürkE. Development of sensitive and specific analysis of vildagliptin in pharmaceutical formulation by gas chromatography-mass spectrometry.J. Anal. Methods Chem.201520151710.1155/2015/70741426682085
     [Google Scholar]
  146. SupriyaP. LathaM.N. KbvR. RamanaG. HariniU. AkmP. Development and validation of UV spectrophotometric and Reversed phase-high performance liquid chromatography-PDA methods for the estimation of alogliptin benzoate.Asian J. Pharm. Clin. Res.201691282287
     [Google Scholar]
  147. Sunil KumarA.V.V.N.K. ReddyT.V. SekharanC.B. Spectrophotometric determination of alogliptin in bulk and tablet dosage form using bromate–bromide mixture as brominating agent.Karbala Int J Mod Sci20173181710.1016/j.kijoms.2016.12.002
     [Google Scholar]
  148. Sunil KumarA.V.V.N.K. ReddyT.V. SekharanC.B. Utility of picric acid and 2,4 dinitrophenol as chromogenic reagents for visible spectrophotometric quantification of alogliptin.Bull. Fac. Pharm. Cairo Univ.201755117718410.1016/j.bfopcu.2017.02.002
     [Google Scholar]
  149. YadavP.J. KadamV.N. MohiteS.K. Development and validation of UV spectrophotometric method for alogliptin benzoate in bulk drug and tablet formulation.Int. J. Curr. Pharm. Res.2014441286129010.33786/JCPR.2014.v04i04.004
     [Google Scholar]
  150. SharmaK. ParleA. Development and validation of HPTLC method for estimation of Alogliptin benzoate in bulk drugs and tablet dosage forms.Int Bullet Drug Res2015588189
     [Google Scholar]
  151. PatilK.R. DeshmukhT.A. PatilV.R. Stability indicating high performance thin layer chromatographic determination of alogliptin benzoate as bulk drug and in tablet dosage form.Am J Pharmtech Res20199333234310.46624/ajptr.2019.v9.i3.028
     [Google Scholar]
  152. SuratiJ.S. PatelV.B. Study of degradation behaviour of alogliptin benzoate by stability indicating high performance thin layer chromatographic method.Asian J. Chem.20172971607161110.14233/ajchem.2017.20614
     [Google Scholar]
  153. BodiwalaK.B. ShahS. ThakorJ. MaroliaB. PrajapatiP. Degradation kinetics study of alogliptin benzoate in alkaline medium by validated stability-indicating HPTLC method.J. AOAC Int.20169961505151210.5740/jaoacint.16‑012027608919
     [Google Scholar]
  154. NaseefH. MoqadiR. QurtM. Development and validation of an HPLC method for determination of antidiabetic drug alogliptin benzoate in bulk and tablets.J. Anal. Methods Chem.201820181710.1155/2018/190251030345140
     [Google Scholar]
  155. BertolC.D. FriedrichM.T. CarlosG. FroehlichP.E. Analytical stability-indicating methods for alogliptin in tablets by LC-CAD and LC-UV.J. AOAC Int.2017100240040510.5740/jaoacint.16‑018328118563
     [Google Scholar]
  156. HammadS.F. AbdallahI.A. BedairA. MansourF.R. Salting-out induced liquid–liquid microextraction for alogliptin benzoate determination in human plasma by HPLC/UV.BMC Chem.2021151210.1186/s13065‑020‑00729‑833451337
     [Google Scholar]
  157. WadhankarS JaiswalN BadwaikI MangeM RandiveT. HPLC method for determination of gliptin as antidiabetic drug in bulk and tablets.TIJER - Int J Res202310272432
     [Google Scholar]
  158. RaoG.S. MalleshK. KumarG.V. SurekhaCh. RaoB.V. A validated chiral HPLC method for the enantiomeric purity of Alogliptin benzoate.Pharma Chem201463234239
     [Google Scholar]
  159. ZhouY. ZhouW. SunL. ZouQ. WeiP. OuYangP. Characterization of process‐related impurities including forced degradation products of alogliptin benzoate and the development of the corresponding reversed‐phase high‐performance liquid chromatography method.J. Sep. Sci.201437111248125510.1002/jssc.20130138424616424
     [Google Scholar]
  160. MadhukarA. FathimaA. UshaA. KumarA.S.C. KumarP.A. UshaK. RP-HPLC method development and validation of alogliptin bulk and tablet dosage form.Indo Am J Pharm Sci2018542897290410.5281/zenodo.1228358
     [Google Scholar]
  161. GsS. C JGB, T TM. Validated RP-HPLC method for the quatitation of alogliptin in bulk and tablet dosage form.Am J Pharmtech Res20188214014810.46624/ajptr.2018.v8.i2.010
     [Google Scholar]
  162. VinyasM. VelivelaS. YadavG. PatiN.B. GuptaV.R.M. Analytical method development and validation of alogliptin by RP-HPLC method.Res J Pharm Technol20169777577810.5958/0974‑360X.2016.00148.7
     [Google Scholar]
  163. KantR. BodlaR.B. BhutaniR. KapoorG. Enantioselective box behenken optimized hplc-dad method for the simultaneous estimation of alogliptin enantiomorphs in pharmaceutical formulations and their pharmacokinetic study in rat plasma.Adv. Pharm. Bull.20199114715810.15171/apb.2019.018
     [Google Scholar]
  164. ZhangK. MaP. JingW. ZhangX. A developed HPLC method for the determination of Alogliptin Benzoate and its potential impurities in bulk drug and tablets.Asian J Pharm Sci201510215215810.1016/j.ajps.2015.01.001
     [Google Scholar]
  165. YadavP.J. JadhavS.S. MohiteS.K. Development and validation of RP-HPLC method for Alogliptin benzoate in bulk drug and dosage form.Int. J. Pharm. Pharm. Res.20141219
     [Google Scholar]
  166. DhamireddyS SubudhiSK VeeramallaS KallepelliS CheripelliS SadashivNS RP-HPLC method development and validation of Alogliptin tablet dosage form.IJARMPS2019411
     [Google Scholar]
  167. DaswadkarS.C. RoyM.A. WalodeS.G. Mahendra KumarC.B. Optimization of RP-HPLC method for determination of Alogliptin benzoate in bulk and dosage form.Int. J. Chem. Sci.2016142649660
     [Google Scholar]
  168. BagaryE.R.I. ElkadyE.F. AyoubB.M. Liquid chromatographic determination of alogliptin in bulk and in its pharmaceutical preparation.Int. J. Biomed. Sci.201283215218
     [Google Scholar]
  169. RaviY. RajkamalB.B. A validated LC-MS/MS method for the pharmacokinetic study of alogliptin in healthy rabbits.J. Appl. Pharm. Sci.201992293710.7324/JAPS.2019.90204
     [Google Scholar]
  170. LuY. YangD. LiZ. HangT. SongM. Isolation and characterization of related substances in alogliptin benzoate by LC-QTOF mass spectrometric techniques.J. Pharm. Biomed. Anal.201612825326310.1016/j.jpba.2016.04.03227281581
     [Google Scholar]
  171. Al-SabtiB. HarbaliJ. HPLC–MS analysis of four potential genotoxic impurities in alogliptin pharmaceutical materials.J. AOAC Int.2022105236236910.1093/jaoacint/qsab15234849990
     [Google Scholar]
  172. MuralikrishnaR. RaoA.L. UPLC-MS/MS assay for Alogliptin in human plasma and its pharmacokinetic application.Int. J. Res. Pharm. Chem.201774558569
     [Google Scholar]
  173. GorumutchuG.P. RatnakaramN.V. KishoreV.N.V. Visible spectrophotometric determination of gemigliptin using charge transfer complex.Orient. J. Chem.201935269469910.13005/ojc/350226
     [Google Scholar]
  174. ChoY.S. LeeS.H. LimH.S. BaeK.S. Pharmacokinetic equivalence of the high dose strength fixed-dose combination tablet of gemigliptin/metformin Sustained Release (SR) and individual component gemigliptin and metformin XR tablets in healthy subjects.J. Korean Med. Sci.20183341e25810.3346/jkms.2018.33.e25830288156
     [Google Scholar]
  175. KhanH. ShelkeV.P. Development and validation of RP-HPLC method for the estimation of gemigliptin.Int. J. Pharm. Pharm. Res.2018132224231
     [Google Scholar]
  176. LuharS.V. PatelK.R. JaniG.K. NarkhedeS.B. Stability study of gemigliptin and simultaneous estimation of gemigliptin and its degradation product by RP-HPLC method.J Pharmaceut Sci Bioscient Res201663338346
     [Google Scholar]
  177. LuharS.V. PatelH.A. JaniG.K. MalairajanP. Bioanalytical method development and validation of gemigliptin tartrate sesquihydrate.Eur J Biomed Pharm Sci201744488501
     [Google Scholar]
  178. ChoiH.Y. NohY.H. KimY.H. KimM.J. LeeS.H. KimJ.A. Effects of food on the pharmacokinetics of a gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixed-dose combination tablet in healthy male volunteers.Int. J. Clin. Pharmacol. Ther.2014525381391
     [Google Scholar]
  179. ShinD. ChoY.M. LeeS. Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.Clin. Drug Investig.201434638339310.1007/s40261‑014‑0184‑324627290
     [Google Scholar]
  180. ChoiH.Y. KimY.H. KimM.J. Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers.Drugs R D.201414316517610.1007/s40268‑014‑0054‑824962635
     [Google Scholar]
  181. EmanuelliJ. SchapovalS.S.E. Stability-Indicating HPLC method for estimation of omarigliptin in tablets – Oxidative and photolytic kinetics and degradation products formed under oxidative conditions.Microchem. J.202015710508410.1016/j.microc.2020.105084
     [Google Scholar]
  182. TantawyM.A. HassanA.M. HegazyM.A. KelaniK.M. Quality and stability profile assessment of the recent antidiabetic omarigliptin by using different chromatographic methods.J. Chromatogr. Sci.202159876276910.1093/chromsci/bmaa13633434917
     [Google Scholar]
  183. MowakaS. AshoushN. TadrosM. El ZaharN. AyoubB. Enhanced extraction technique of omarigliptin from human plasma—applied to biological samples from healthy human volunteers.Molecules20202518423210.3390/molecules2518423232942678
     [Google Scholar]
  184. BiftuT. Sinha-RoyR. ChenP. Omarigliptin (MK-3102): A novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.J. Med. Chem.20145783205321210.1021/jm401992e24660890
     [Google Scholar]
  185. LiM.F. HuX.X. MaA.Q. Ultra‐high pressure liquid chromatography–tandem mass spectrometry method for the determination of omarigliptin in rat plasma and its application to a pharmacokinetic study in rats.Biomed. Chromatogr.20173110e397510.1002/bmc.397528317144
     [Google Scholar]
  186. PatilA.S. ShirkhedkarA.A. Development and validation of five simple UV-spectrophotometry methods for estimation of anagliptin in bulk and in-house tablets.Pharm. Methods20167212713110.5530/phm.2016.7.19
     [Google Scholar]
  187. PatilA. ShirkhedkarA. Application of quality by design in the development of HPTLC method for estimation of anagliptin in bulk and in-house tablets.Eurasian J Anal Chem201712544345810.12973/ejac.2017.00181a
     [Google Scholar]
  188. PandyaC.P. RajputS.J. Stress degradation studies of anagliptin, development of validated stability indicating method, degradation kinetics study, identification and isolation of degradation products.Chromatographia201881111533155010.1007/s10337‑018‑3617‑y
     [Google Scholar]
  189. GongA. XuJ. JinD. WangY. ZhuX. Determination of anagliptin in serum by mixed-hemimicelle magnetic solid-phase extraction with surfactant-coated iron(II, III) nanocomposites and high-performance liquid chromatography.Anal. Lett.201851152415242810.1080/00032719.2018.1431245
     [Google Scholar]
  190. MalleswarK.D. RaoB.V. ShylajaS. A validated chiral HPLC method for the enantiomeric purity of anagliptin.Indo Am J Pharm Res20199730963101
     [Google Scholar]
  191. HemkeA.T. YadavA.S. KapgateM.M. UmekarM.J. Determination of intrinsic stability and development of validated stability indicating RP-HPLC method for anagliptin.J. Glob. Trends Pharm. Sci.202011381818190
     [Google Scholar]
  192. BairaS.M. SigalapalliD.K. BathiniN.B. R S, Talluri MVNK. LC/QTOF/MS/MS characterization, molecular docking and in silico toxicity prediction studies on degradation products of anagliptin.J. Pharm. Biomed. Anal.2018159929910.1016/j.jpba.2018.06.03629980024
     [Google Scholar]
  193. FurutaS. TamuraM. HirookaH. MizunoY. MiyoshiM. FurutaY. Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs.Eur. J. Drug Metab. Pharmacokinet.2013382879610.1007/s13318‑013‑0119‑z23436178
     [Google Scholar]
  194. YadavN. GoyalA. Method development and validation of Teneligliptin in pharmaceutical dosage form by UV spectrophotometric methods.Int J Pharm Chem Anal201743545810.18231/2394‑2797.2017.0014
     [Google Scholar]
  195. DeoreK.R. KalkotwarR.S. Development and validation of stability indicating UV spectrophotometric method for the estimation of teneligliptin in bulk and tablet dosage form.Int J Adv Eng Manag2021373869387110.35629/5252‑030738693871
     [Google Scholar]
  196. PatraP. GhoshS. RoyT. kumar RBVV. A novel spectrophotometric method development and validation of Tenagliptin in its Tablet dosages form.J. Drug Deliv. Ther.201995959810.22270/jddt.v9i5.3503
     [Google Scholar]
  197. TighareK.V. SawaleA.V. Development and validation of stress degradation studies for quantification of teneligliptin by UV spectroscopic method.World J. Pharm. Res.202110790291810.20959/wjpr20217‑20784
     [Google Scholar]
  198. Comparative evaluation of dissolution profile of drug in its formulation by UV spectrophotometry.Int J Pharm Chem Anal202071263110.18231/j.ijpca.2020.004
     [Google Scholar]
  199. KshirsagarS.A. ManeS.B. HanchateY.S. KatteA.S. KulkarniK.V. UV spectrophotometric method development and validation for determination of teneligliptin hydrobromide hydrate in API and in pharmaceutical dosage form.Int J Pharm Res Schol201871192710.31638/IJPRS.V7.I1.00008
     [Google Scholar]
  200. ChitlangeS.S. RawatD.G. ChandaniS. Estimation of anti-diabetic teneligliptin hydrobromide hydrate by RP-HPLC and derivative spectroscopic method.Indo Am J Pharm Res20166761446153
     [Google Scholar]
  201. FarkadeK. TawarM. Analytical method validation and quantitative analysis for active pharmaceutical ingredient and marketed formulation of teneligliptin hydrobromide by UV spectroscopy.Asian J Pharm Anal202111319519810.52711/2231‑5675.2021.00034
     [Google Scholar]
  202. MaruthiR. ChandanR.S. BarathM. Analytical method development and validation of teneligliptin by UV spectroscopy.Res J Pharm Technol2021141757810.5958/0974‑360X.2021.00014.7
     [Google Scholar]
  203. KaradM.D. BarhateV.D. Spectrophotometric determination of an antidiabetic drug teneligliptin bulk and pharmaceutical formulations.World J. Pharm. Res.2016551625163210.20959/wjpr20165‑6222
     [Google Scholar]
  204. GhugeB.S. PendhariS.S. MalodeP.A. AnantwarS.P. Development and validation of simple UV spectrophotometric method for the determination of teneligliptin hydrobromide hydrate in API and its bulk dosage form.Int J Pharm Res Schol2017624453
     [Google Scholar]
  205. PatilP.M. JainP.S. SuranaS.J. YeoleS.D. Development and validation of high-performance thin-layer chromatography method for estimation of teneligliptin in bulk and in pharmaceutical formulation.Acta Chimic Pharmaceut Indica201773112
     [Google Scholar]
  206. LodhaS.R. PatelK.D. PatelS.A. PatelS.G. BodiwalaK.B. ShahS.A. Development and validation of HPTLC method for estimation of teneligliptin hydrobromide hydrate in tablet dosage form.J Pharm Appl Sci2016312633
     [Google Scholar]
  207. ShahD.A. AgarwalK. MehtaF.A. PatelV.B. Stability indicating HPTLC method for the estimation of anti-diabetic drug teneligliptin.Curr. Pharm. Anal.201814654755410.2174/1573412913666170918160514
     [Google Scholar]
  208. ShindeV.C. AherK.B. BhavarG.B. KakadS.J. ChaudhariS.R. Development and validation of UV spectrophotometric method and high-performance thin layer chromatographic (HPTLC) method for estimation of teneligliptin hydrobromide in pharmaceutical preparation.Pharm. Lett.20168291301
     [Google Scholar]
  209. AshwiniB.S. NitinD.V. AshwiniS.C. VishnuS.C. Analytical method development and validation of teneligliptin hydrobromide in pure form by HPLC.World J. Pharm. Pharm. Sci.20175103748
     [Google Scholar]
  210. NakamaruY. HayashiY. IkegawaR. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans.Xenobiotica201444324225310.3109/00498254.2013.81689123855261
     [Google Scholar]
  211. JadhaoM.P. GameM.D. DangeV.H. Implementation of quality by design study on analytical method development and validation of teneligliptin hydrobromide.Int J Chem Pharm Anal20186111110.21276/ijcpa
     [Google Scholar]
  212. PatelB.D. DharsandiyaN.J. ChaudharyA. Development and validation of RP-HPLC method for estimation of teneligliptin and its impurity in tablet.Int. J. Pharm. Sci. Rev. Res.202169212713310.47583/ijpsrr.2021.v69i02.019
     [Google Scholar]
  213. ChandanaM. RaoM.P. SamrajyamB. SireeshaK.S.K.D. Analytical method development and validation of teneligliptin in pharmaceutical dosage form by RP-HPLC method.IJRDO-J Health Sci Nurs2016112112
     [Google Scholar]
  214. TighareK.V. SawaleA.V. Method development, validation and stress degradation study of teneligliptin by RP-HPLC.American Journal of PharmTech Research2021113365010.46624/ajptr.2021.v11.i3.004
     [Google Scholar]
  215. DahikarG.D. BobadeG. Development and validation of stability indicating RP-HPLC method for teneligliptin hydrobromide hydrate.Am J Pharmtech Res202111111210.46624/ajptr.2021.v11.i1.001
     [Google Scholar]
  216. P N, Siva KumarR. Bioanalytical method development and validation of teneligliptin using RP-HPLC in rabbit plasma.World J. Pharm. Res.201761058960210.20959/wjpr201710‑9225
     [Google Scholar]
  217. LokhandeDP Analytical method development and validation of teneligliptin by using RP-HPLC with ICH guidelines.IJTSRD20193-32596310.31142/ijtsrd21735
     [Google Scholar]
  218. BiswasB. KumarM. SharmaJ.B. SainiV. BhattS. Method development and validation for estimation of teneligliptin in tablet dosage form by RP-HPLC.Res J Pharm Technol20201341774177810.5958/0974‑360X.2020.00320.0
     [Google Scholar]
  219. NagarajanK.P.R.G.A.B.P.G. Development and validation of fast and sensitive RP-HPLC stability indicating method for quantification of teneligliptin in bulk drug.J. Chromatogr. Sci.20232023bmad061
     [Google Scholar]
  220. PulateC. TareH. DamaG. Method development and validation of teneligliptin by RP-HPLC method.Int. J. Biol. Pharm. Allied Sci.2021101011111810.31032/IJBPAS/2021/10.10.1010
     [Google Scholar]
  221. DandgeV.D. MalveV. WaghulkarV.M. BaituleA.W. JawarkarS.G. Development and validation of a bioanalytical method for determination of teneligliptin in human plasma by RP-HPLC.Int. J. Pharm. Tech. Res.202220222485710.20902/IJPTR.2022.150204
     [Google Scholar]
  222. KumarT.N.V.G. VidyadharaS. NarkhedeN.A. SilpaY.S. LakshmiM.R. Method development, validation, and stability studies of teneligliptin by RP-HPLC and identification of degradation products by UPLC tandem mass spectroscopy.J. Anal. Sci. Technol.2016712710.1186/s40543‑016‑0107‑4
     [Google Scholar]
  223. KumariV.M. EswarammaP. Analytical method development and validation of teneligliptin in pharmaceutical dosage form by RP-HPLC.Eur J Biomed Pharm Sci201746477481
     [Google Scholar]
  224. GanorkarV.A. JibhkateS.R. RadheshyamG.K. Development of stability indicating and robust RP-HPLC method for determination of teneligliptin.Asian J Appl Chem Res20181411210.9734/ajacr/2018/v1i49701
     [Google Scholar]
  225. PudiR. MukthinuthalapatiM.A. Validated isocratic liquid chromatographic method for the quantification of teneligliptin in the presence of internal standard.Int J Green Pharm2018123670674
     [Google Scholar]
  226. MukthinuthalapatiM.A. AlmasS. BaswaniR. AngirekulaN. Stability indicating ultrafast liquid chromatographic method for the estimation of Teneligliptin (An Anti-diabetic agent).Asian J. Pharm.2018122477483
     [Google Scholar]
  227. MaruthiR. ChandanR.S. BarathM. Analytical method development and validation of teneligliptin by RP-UFLC.Res J Pharm Technol20201394035404010.5958/0974‑360X.2020.00713.1
     [Google Scholar]
  228. PaulD. AllakondaL. SatheeshkumarN. A validated UHPLC-QTOF-MS method for quantification of metformin and teneligliptin in rat plasma: Application to pharmacokinetic interaction study.J. Pharm. Biomed. Anal.20171431810.1016/j.jpba.2017.05.02628544884
     [Google Scholar]
  229. ShantikumarS. SatheeshkumarN. SrinivasR. Pharmacokinetic and protein binding profile of peptidomimetic DPP-4 inhibitor – Teneligliptin in rats using liquid chromatography–tandem mass spectrometry.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.2015100219420010.1016/j.jchromb.2015.08.02326340762
     [Google Scholar]
  230. MaruthiR. ChandanR.S. TengliA.K. Characterization of impurities in teneligliptin hydrobromide hydrate by using LCMS/MS and NMR.Res J Pharm Technol20201383569357610.5958/0974‑360X.2020.00631.9
     [Google Scholar]
  231. HalabiA. MaatoukH. SieglerK.E. FaisstN. LufftV. KlauseN. Pharmacokinetics of teneligliptin in subjects with renal impairment.Clin. Pharmacol. Drug Dev.20132324625410.1002/cpdd.2927121786
     [Google Scholar]
  232. OgumaT. KuriyamaC. NakayamaK. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.J. Pharmacol. Sci.2015127445646110.1016/j.jphs.2015.03.00625892328
     [Google Scholar]
  233. MowakaS. AyoubB.M. HassanM.A. ZagharyW.A. Different spectrophotometric methods for simultaneous determination of trelagliptin and its acid degradation product.J. Anal. Methods Chem.201820181710.1155/2018/737065129629213
     [Google Scholar]
  234. ZagharyW.A. MowakaS. HassanM.A. AyoubB.M. Suitability of various chromatographic and spectroscopic techniques for analysis and kinetic degradation study of trelagliptin.Sci. Rep.2017711725510.1038/s41598‑017‑17642‑129222475
     [Google Scholar]
  235. LuoZ. ChenX. WangG. Development of a validated HPLC method for the quantitative determination of trelagliptin succinate and its related substances in pharmaceutical dosage forms.Eur. J. Pharm. Sci.201811145846410.1016/j.ejps.2017.10.02829066384
     [Google Scholar]
  236. MalleswarK.D. RaoB.V. RaoK.V. ShylajaS. A validated chiral HPLC method for the enantiomeric purity of trelagliptin.Indo Am J Pharm Res201991158258710.5281/zenodo.3559498
     [Google Scholar]
  237. WangQ. ChenX. ZhangC. Determination of the enantiomeric purity of trelagliptin by pre-column derivatization and liquid chromatography on a chiral stationary phase.Chromatographia201578211395140010.1007/s10337‑015‑2946‑3
     [Google Scholar]
  238. AneraoA. MundekarV. JohnS. PradhanN. Development and validation of related substances method by HPLC for analysis of trelagliptin succinate.World J. Pharm. Pharm. Sci.2016581844185810.20959/wjpps20168‑7509
     [Google Scholar]
  239. ZhangH. SunL. ZouL. Identification, characterization and HPLC quantification of process-related impurities in Trelagliptin succinate bulk drug: Six identified as new compounds.J. Pharm. Biomed. Anal.2016128182710.1016/j.jpba.2016.04.04127209451
     [Google Scholar]
  240. HanY. ChenL. LiuW. An HPLC–MS/MS method for quantitation of trelagliptin and application in a comparative pharmacokinetic study.Bioanalysis201911191755176510.4155/bio‑2018‑023831648536
     [Google Scholar]
  241. ZhouL. XiW. ZhangH. SunL. YuJ. ZouQ. The chiral bioconversion and pharmacokinetic analysis of trelagliptin in beagle dog plasma by LC-MS/MS.J. Chromatogr. Sci.2020581313610.1093/chromsci/bmz10531844877
     [Google Scholar]
  242. HuX.X. LanT. ChenC.C. A rapid and sensitive UHPLC–MS/MS assay for the determination of trelagliptin in rat plasma and its application to a pharmacokinetic study.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.201620161033103410.1016/j.jchromb.2016.08.024
     [Google Scholar]
  243. Purushottam AgrawalY. AgrawalM.Y. JadhavS.B. ShindeR.J. Development and validation of novel UV spectrophotometric method for the determination of evogliptin tartarate in pharmaceutical dosage form.Indian J Pharm Educ Res20205441174117910.5530/ijper.54.4.214
     [Google Scholar]
  244. PatelK. ShahU. JoshiH. PatelC.N. Derivative spectrophotometric method development and validation for the estimation of evogliptin tartrate in pharmaceutical dosage form.Indian J Pharm Educ Res202357122823310.5530/001954640245
     [Google Scholar]
  245. SrivastavaS. DhaneshwarS. KawathekarN. Stability-indicating densitometric analysis of evogliptin tartrate in bulk and tablet dosage form.J. AOAC Int.202310661471147710.1093/jaoacint/qsad09137531285
     [Google Scholar]
  246. AhirH.M. DamaheD.P. NarkhedeS.B. Development and validation of stability indicating RP-HPLC method for the estimation of evogliptin tartrate in pharmaceutical dosage form.Int. J. Pharm. Sci. Rev. Res.20227221610.47583/ijpsrr.2022.v72i02.001
     [Google Scholar]
  247. DolasJ. JawarkaS. RodeR.J. ChinchulkarG. KhanM. Novel method development, validation, and stability indicating assay method for evogliptin tartrate in pharmaceutical dosage form by RP-HPLC.J. Emerg. Technol. Innov. Res.202292b327b345
     [Google Scholar]
  248. ChandakavatheB.N. RajmaneA.D. ShiddanagoudarO.J. BetS.P. Development and validation of RP-HPLC method for estimation of evogliptin in formulation.Int. J. Pharm. Pharm. Res.2023263360368
     [Google Scholar]
  249. PatelK. ShahU.A. PatelC.N. Box–Behnken design-assisted optimization of RP-HPLC method for the estimation of evogliptin tartrate by analytical quality by design.Futur J Pharm Sci2023915710.1186/s43094‑023‑00509‑w
     [Google Scholar]
  250. PatelA. PatelR. YadavP. Development and validation of RP-HPLC method for estimation of evogliptin in pharmaceutical dosage form.IJPRA2021622249778110.35629/7781‑0602775781
     [Google Scholar]
  251. JeongH.U. KimJ.H. LeeD. ShimH. LeeH. McPheeD.J. In vitro metabolic pathways of the new anti-diabetic drug evogliptin in human liver preparations.Molecules20152012218022181510.3390/molecules20121980826690104
     [Google Scholar]
  252. LeeD.Y. KimJ.H. ShimH.J. JeongH.U. LeeH.S. Absorption, metabolism, and excretion of [14C]evogliptin tartrate in male rats and dogs.J. Toxicol. Environ. Health A2018811145346410.1080/15287394.2018.145119429557727
     [Google Scholar]
  253. ChoK. JoungS.K. LaS. Bioanalytical validation for the determination of evogliptin and its metabolites m7/m8 in human plasma by liquid chromatography-tandem mass spectrometry.Drug Metab. Pharmacokinet.2017321S2710.1016/j.dmpk.2016.10.12728131653
     [Google Scholar]
  254. HwangI. KimY. YooH. JangI.J. YuK.S. LeeS. Pharmacokinetic/pharmacodynamic interaction between evogliptin and pioglitazone in healthy male subjects.Drug Des. Devel. Ther.2020144493450210.2147/DDDT.S27533633122892
     [Google Scholar]
  255. YuK-S. RheeS. LeeS.H. YoonS.H. ChoJ-Y. JangI-J. Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects.Drug Des. Devel. Ther.2016101411141810.2147/DDDT.S10245927110098
     [Google Scholar]
  256. OhE.S. ChoiC. KimC.O. Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers.J. Clin. Pharm. Ther.201742668969410.1111/jcpt.1260428806472
     [Google Scholar]
  257. HongT. JinB.H. KimC.O. Pharmacokinetics and safety of evogliptin in hepatically impaired patients.Br. J. Clin. Pharmacol.20218772757276610.1111/bcp.1468033245796
     [Google Scholar]
  258. ClauxO. SanterreC. Abert-VianM. TouboulD. ValletN. ChematF. Alternative and sustainable solvents for green analytical chemistry.Curr. Opin. Green Sustain. Chem.20213110051010.1016/j.cogsc.2021.100510
     [Google Scholar]
  259. KayaS.I. CetinkayaA. OzkanS.A. Green analytical chemistry approaches on environmental analysis.Trends Environ Anal Chem202233e0015710.1016/j.teac.2022.e00157
     [Google Scholar]
  260. UllahN. HaseebA. TuzenM. Application of recently used green solvents in sample preparation techniques: A comprehensive review of existing trends, challenges, and future opportunities.Crit. Rev. Anal. Chem.2023202312010.1080/10408347.2023.219749537067946
     [Google Scholar]
  261. GaikwadJ. SharmaS. HatwareK.V. Review on characteristics and analytical methods of tazarotene: An update.Crit. Rev. Anal. Chem.2020501909610.1080/10408347.2019.158651930942085
     [Google Scholar]
/content/journals/cdr/10.2174/0115733998288292240409060854
Loading
Analytical and Bioanalytical Methods for the Determination of Dipeptidyl Peptidase-4 Inhibitors in Various Matrices: A Comprehensive Review
Curr. Diabetes Rev. 21, E030524229629 (2025); https://doi.org/10.2174/0115733998288292240409060854
/content/journals/cdr/10.2174/0115733998288292240409060854
/content/journals/cdr/10.2174/0115733998288292240409060854
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): diabetes mellitus; DPP-4 Inhibitors; gliptins; HPLC; kidney disease; pharmacokinetics

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test